Evaluation of a risk-sharing agreement for atezolizumab treatment in patients with non-small cell lung cancer: a strategy to improve access in low-income countries
Implementing RSAs can optimize resource allocation, making IO treatment more accessible, especially in low-income countries.
Authors
- Herman Soto–Molina (ORCID: https://orcid.org/0000-0001-8479-4407)
- A. Valencia-Velarde
- Silvia Guzmán Vázquez (ORCID: https://orcid.org/0000-0003-0476-4289)
- Óscar Arrieta (ORCID: https://orcid.org/0000-0002-1164-3779)
- Maritza Ramos-Ramírez (ORCID: https://orcid.org/0000-0002-1787-0665)
- Luis A. Cabrera-Miranda
- Marco A. Galvez Nino (ORCID: https://orcid.org/0000-0002-1408-4474)
- Andrés F. Cardona (ORCID: https://orcid.org/0000-0003-3525-4126)
- Ana Pamela Gómez-García (ORCID: https://orcid.org/0000-0002-9392-1647)
- Homero Garcés-Flores
Institutions
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- Instituto Nacional de Cardiología (MX)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-10-19
- DOI
- https://doi.org/10.1093/oncolo/oyae272
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57